SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects

Conditions

• Inflammatory Disorder of the Respiratory Tract
• Chronic Obstructive Pulmonary Disorder

Interventions

• DRUG: RPL554
• DRUG: Placebo

Sponsor

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA